Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies

Allman, M., Tallantyre, E. ORCID: https://orcid.org/0000-0002-3760-6634 and Robertson, N. P. ORCID: https://orcid.org/0000-0002-5409-4909 2022. Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies. Journal of Neurology 269 (4) , pp. 2259-2261. 10.1007/s00415-022-11053-7

PDF - Published Version Available under License Creative Commons Attribution. Download (441kB)

Abstract

The COVID-19 pandemic has caused significant mortality and morbidity throughout the world, with vaccination against the SARS-CoV-2 virus now widely considered the most effective strategy to minimise clinical impact. However, people with multiple sclerosis (pwMS), treated with disease modifying therapies (DMTs), which target and supress varying components of the immune response, are considered more vulnerable to severe disease. Furthermore, recovery and immunity from COVID-19 relies on an effective immune response to specific components of the SARS-CoV-2 virus and it is unclear whether pwMS on DMTs are able to consistently develop adequate, durable protection. This month’s journal club describes four papers that aim to answer questions surrounding this issue.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Additional Information:	This article is licensed under a Creative Commons Attribution 4.0 International License
Publisher:	Springer
ISSN:	0340-5354
Date of First Compliant Deposit:	9 May 2022
Date of Acceptance:	24 February 2022
Last Modified:	08 May 2023 08:19
URI:	https://orca.cardiff.ac.uk/id/eprint/149619

Citation Data

Cited 1 time in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item